U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07946601) titled 'Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy' on Nov. 12.
Brief Summary: This study is for participants who have recently been diagnosed with muscle-invasive bladder cancer (MIBC) who are eligible for the surgical removal of the entire bladder, and have undergone ctDNA testing with a negative result. The purpose of this study is to investigate the outcomes for ctDNA negative MIBC participants who do not receive neoadjuvant chemotherapy before undergoing bladder removal.
Study Start Date: Jan., 2027
Study Type: INTERVENTIONAL
Condition:
Muscle Invasive Bladder Cancer (MIBC)
Interventio...